In this large US-based real-world study of patients with ALK-positive advanced NSCLC treated with 1L alectinib or brigatinib, we describe contemporary sequencing patterns and treatment effectiveness of 1L and 2L treatments. This evidence concerns the gene ALK and non-small cell lung carcinoma.